시장보고서
상품코드
2132955

생분해성 의료용 폴리머 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Biodegradable Medical Polymer Market Report: Trends, Forecast and Competitive Analysis to 2035

발행일: | 리서치사: 구분자 Lucintel | 페이지 정보: 영문 150 Pages | 배송안내 : 3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

가격
PDF, Excel & 1 Year Online Access (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,850 금액 안내 화살표 ₩ 6,615,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF & Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,700 금액 안내 화살표 ₩ 9,139,000
PDF, Excel & 1 Year Online Access (Corporate License) help
PDF & Excel 보고서를 동일 기업 내 동일 국가의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,850 금액 안내 화살표 ₩ 12,072,000
PDF, Excel & 1 Year Online Access (Global License) help
PDF & Excel 보고서를 동일 기업(완전 자회사 포함)의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 금액 안내 화살표 ₩ 13,641,000
※ 부가세 별도
한글목차
영문목차

생분해성 의료용 폴리머 시장

전 세계 생분해성 의료용 폴리머 시장의 미래는 약물전달, 임플란트, 봉합사 각 시장의 기회를 바탕으로 밝은 전망을 보이고 있습니다. 전 세계 생분해성 의료용 폴리머 시장은 2027년 40억 달러에서 2035년까지 약 130억 달러에 달할 것으로 예상되며, 2027-2035년까지 연평균 성장률(CAGR)은 16.9%에 달할 것으로 전망됩니다. 이 시장의 주요 성장 동인으로는 최소 침습 수술에 대한 선호도 증가, 첨단 약물전달 시스템에 대한 수요 증가, 생체흡수성 의료용 임플란트의 채택 확대 등이 꼽힙니다.

  • Lucintel의 예측에 따르면 소재 유형별로는 세라믹 매트릭스 복합 소재가 첨단 용도에서 뛰어난 열 안정성과 기계적 강도를 바탕으로 예측 기간 중 더 높은 성장세를 보일 것으로 전망됩니다.
  • 용도별로는 제어된 표적 지향형 약물전달 방식의 채택이 진행되고 있는 만큼, 예측 기간 중 약물전달 분야가 가장 높은 성장률을 보일 것으로 예상됩니다.
  • 지역별로는 나노테크놀러지 연구가 활발하고 제약 제조 능력이 확대되고 있으며, 예측 기간 중 북미가 최대 시장 규모를 유지할 것으로 전망됩니다.

생분해성 의료용 폴리머 시장의 새로운 동향

2024-2027년에 생분해성 폴리머의 용도는 봉합사나 약물 코팅에 그치지 않고, 구조용 심혈관 스캐폴드 및 3D 프린팅을 통한 맞춤형 임플란트로 확대되었습니다. Lucintel의 보고서에 따르면 이러한 혁신은 의료기기 제조업체들이 선호하는 폴리머의 화학 조성 및 제조 기술에 영향을 미칠 것으로 보입니다.

  • 3D 프린팅을 통한 맞춤형 스캐폴드: 3D 프린팅 의료기기 분야에서 적층 제조 기술을 통해 생체흡수성 스캐폴드의 환자 맞춤형 설계가 가능해졌으며, 3D 프린팅은 생체흡수성 혈관용 스캐폴드의 주요 구현 기술이 되었습니다. 맞춤형 의료의 성장에 따라 심혈관 및 정형외과 분야에서 기성품에서 맞춤형 3D 프린팅 폴리머 스캐폴드로의 전환이 지속적으로 추진될 것으로 보입니다.
  • 흡수성 임플란트에서 폴리젖산의 우위: 폴리젖산(PLA)은 봉합사, 정형외과용 핀, 스캐폴드 등 폭넓은 의료기기 용도에 힘입어 2026년에는 생분해성 폴리머 시장에서 35%의 점유율을 차지하며 시장을 주도할 것입니다. 흡수성 임플란트의 성장에 따라 PLA에 대한 수요는 더욱 높아질 것이며, 그 안전성 실적과 의료기기 가공업체들의 폭넓은 지지를 바탕으로 PLA는 계속해서 지배적인 시장 점유율을 유지할 전망입니다.
  • 약물전달 시스템의 통합: 약물의 서방(徐放)을 목적으로 설계된 생체흡수성 폴리머는 시장에서 점유율을 현저히 확대하고 있으며, 서방형 치료제에 대한 수요가 지속적으로 증가하고 있으며, 2026년에는 약물전달 시스템이 전체 용도의 약 30%를 차지할 것으로 예측됩니다. 약사들 사이에서 국소적이고 서방형 제제에 대한 선호도가 높아지고 있으며, 이러한 폴리머 제제의 적용 범위는 심혈관 및 정형외과 분야를 넘어 확대될 것으로 보입니다.
  • 지역별 제조의 다각화: 과거에는 생분해성 폴리머 원료를 수입에 의존하던 국가들도 현재는 국내에서 생분해성 폴리머를 생산하고 있습니다. 인도에서는 2036년까지 연평균 성장률(CAGR) 19.1%로 생체흡수성 폴리머 제조가 가장 빠르게 성장할 것으로 예측됩니다. 각국이 공급망의 회복탄력성 강화에 힘쓰는 가운데, 이러한 제조의 다각화로 인해 의료용 생분해성 폴리머의 생산 거점은 앞으로도 계속 변화할 것으로 보입니다.
  • 영구 임플란트의 대체: 의료계에서는 영구적인 금속나 합성 임플란트보다 생분해성 소재가 선호되는 추세입니다. 2026년까지 의료 분야는 생분해성 폴리머 총 수요의 약 45%를 차지할 것으로 예상됩니다. 2차 외과적 제거의 필요성을 줄이는 데 중점을 두게 됨에 따라 흡수성 소재는 더 광범위한 임상 용도에서 영구 임플란트를 대체해 나갈 것으로 보입니다.

향후 수년간 생분해성 의료용 폴리머의 영향력은 더욱 커질 것이며, 지금까지 생분해성 임플란트에 의존하지 않았던 새롭고 다양한 분야에서도 영구 임플란트를 대체해 나갈 것임이 분명합니다.

생분해성 의료용 폴리머 시장의 최근 동향

컴파운더와 소재 공급업체들이 전문적인 제조 역량을 확보하고 시장 점유율을 확대해 나가는 가운데, 생분해성 의료용 폴리머와 관련된 인수합병 및 판매 계약은 2024-2026년에 지속적으로 증가할 전망입니다. Lucintel에 따르면 이러한 시장 동향은 이 분야에서 기존의 분산형 및 단일 기업 공급 모델에서 벗어나는 것을 의미합니다.

  • 전략적 인수: 2025년 1월, GEON Performance Solutions는 생체의학용 폴리머, 생체흡수성 폴리머, 그리고 PEEK 및 TPU(열가소성 폴리우레탄 엘라스토머)를 취급하는 창업 36년 차의 컴파운더인 Foster Corporation을 인수했습니다. 이는 GEON에게 2020년 들어 네 번째 인수 사례이며, 의료기기 분야에 서비스를 제공하는 특수 폴리머 컴파운더 간의 추가적인 통합을 의미합니다.
  • 유통망 확대: 2025년 8월, GEON에 의한 인수 이후, Foster Medical Compounds는 북미 및 남미 지역의 의료용 컴파운드 판매 대리점으로 Formerra를 지정했습니다. 이를 통해 Formerra의 헬스케어용 폴리머 유통에 대한 지역적 커버리지가 확대되었습니다. 유통 파트너십을 통해 생체용 폴리머 제조업체는 지역별 판매 네트워크를 구축할 필요 없이 OEM 고객을 위한 생체용 폴리머를 제조할 수 있게 됩니다.
  • 신경 재생용 스캐폴드 기업 인수: 도레이는 2025년 10월, 생분해성 폴리머 기술 및 스캐폴드 솔루션을 활용하여 섬유 및 신경 재생용 스캐폴드 솔루션을 강화하기 위해 일본의 신경 재생용 스캐폴드 기업을 인수했습니다. 재생의료 분야에서의 전문 역량 확보는 신경 스캐폴드 기술을 둘러싼 경쟁이 격화되고 있음을 보여줍니다.
  • 국내 원료 제조에 대한 투자:Balrampur Chini Mills가 인도 라킴푸르 케리에 건설한 ‘Bioyug’ 폴리젖산(PLA) 제조 공장의 제1 유닛이, 288억 인도 루피에 달하는 사탕수수에서 PLA까지의 통합 밸류체인 프로젝트의 일환으로 2025년 2월에 완공되었습니다. 이 프로젝트는 연간 8만 톤의 생산 능력을 목표로 하고 있습니다. 이를 통해 생분해성 봉합사 및 임플란트의 주요 성분인 PLA 원료의 수입 의존도를 낮출 수 있을 것으로 기대됩니다.
  • 의료 응용 센터 개설: 에보닉(Evonik)은 상하이에 자사 최대 규모의 의료기기 응용 센터를 개설하여 아시아 시장을 대상으로 생체흡수성 의료기기 부품의 연구개발 및 가공 서비스를 제공하고 있습니다. 이러한 지역별 응용 센터를 통해 지금까지 프로젝트를 유럽이나 미국에 위탁해야만 했던 고객들은 의료기기 부품의 개발 기간을 단축할 수 있게 되었습니다.

이러한 투자 동향은 생분해성 의료용 폴리머 공급업체들이 인수, 유통, 지역내 제조 투자라는 다각적인 전략을 채택해 나갈 것임을 시사합니다. 이는 향후 수년간 임플란트 및 약물전달 시장에 영향을 미칠 것으로 보입니다.

목차

제1장 개요

제2장 시장 개요

제3장 시장 동향과 예측 분석

제4장 세계의 생분해성 의료용 폴리머 시장 : 재료 유형별

제5장 세계의 생분해성 의료용 폴리머 시장 : 제품 형태별

제6장 세계의 생분해성 의료용 폴리머 시장 : 용도별

제7장 지역별 분석

제8장 북미의 생분해성 의료용 폴리머 시장

제9장 유럽의 생분해성 의료용 폴리머 시장

제10장 아시아태평양의 생분해성 의료용 폴리머 시장

제11장 기타 지역의 생분해성 의료용 폴리머 시장

제12장 경쟁 분석

제13장 기회와 전략 분석

제14장 밸류체인 전체에서 주요 기업의 기업 개요

제15장 부록

KSA

Biodegradable Medical Polymer Market

The future of the global biodegradable medical polymer market looks promising with opportunities in the drug delivery, implant, and suture markets. The global biodegradable medical polymer market is expected to reach an estimated $13 billion by 2035 from $4 billion in 2027 with a CAGR of 16.9% from 2027 to 2035. The major drivers for this market are the growing preference for minimally invasive surgical procedures, the rising demand for advanced drug delivery systems, and the increasing adoption of bioresorbable medical implants.

  • Lucintel forecasts that, within the material type category, ceramic matrix composite is expected to witness higher growth over the forecast period due to the superior thermal stability and mechanical strength for advanced applications.
  • Within the application category, drug delivery is expected to witness the highest growth over the forecast period due to the increasing adoption of controlled and targeted drug delivery.
  • In terms of regions, North America will remain the largest region over the forecast period due to the strong nanotechnology research and expanding pharmaceutical manufacturing capabilities.

Emerging Trends in Biodegradable Medical Polymer Market

During 2024-27, biodegradable polymers moved beyond sutures and drug coatings into structural cardiovascular scaffolds and 3D printed personalized implants. Lucintel reports that this innovation will impact the polymer chemistries and manufacturing technologies that will win device maker preference.

  • 3D Printed Personalized Scaffolds: In the field of 3D printed devices, additive manufacturing has enabled patient specific design of bioresorbable scaffolds, and 3D printing is the primary enabler of bioresorbable vascular scaffolds. The growth of personalized medicine will continue to drive the shift from off-the-shelf to customized 3D printed polymer scaffolds across cardiovascular and orthopedic applications.
  • Polylactide's Dominance in Absorbable Implants: Polylactic acid (PLA) dominates the biodegradable polymer market in 2026 with a 35% share, driven by broad medical device applications across sutures, orthopedic pins and scaffolds. The growth in absorbable implants will create further demand for PLA, and retain its dominant share due to its safety record and broad device processor preference.
  • Integration of Drug Delivery Systems: Bioresorbable polymers designed for controlled release of drugs are gaining significant share of the market with drug delivery systems projected to comprise some 30% of total applications in 2026 due to the continuously increasing demand for controlled release therapeutics. Pharmacists' growing preference for localized, controlled release drug formulations will enhance the scope of these polymer formulations beyond cardiovascular and orthopedic applications.
  • Regional Manufacturing Diversification: Those countries that previously relied on imported biodegradable polymer feedstock now are producing biodegradable polymers domestically. India is projected to have the fastest growing bioresorbable polymer manufacture at a 19.1% CAGR until 2036. As countries work on building supply chain resilience, this manufacturing diversification will keep shifting the location of manufacture for medical grade biodegradable polymers.
  • Permanent Implant Replacement: Biodegradable materials are being preferred by the healthcare community over permanent metallic or synthetic implants. By 2026, the healthcare sector is anticipated to comprise around 45% of the total biodegradable polymer demand. With the focus being placed on reducing the need for secondary surgical removals, absorbable materials will displace permanent implants across a broader scope of clinical applications.

It's apparent that over the coming years, medical polymers that are biodegradable will have an even larger impact and will displace permanent implants in new, diverse regions that previously never relied on biodegradable implants.

Recent Developments in the Biodegradable Medical Polymer Market

Consolidation and distribution agreements for biodegradable medical polymers will continue to grow 2024 to 2026, as compounders and materials suppliers look to secure specialized manufacturing capacity and widen their market share. According to Lucintel, these market trends break with the traditional fragmented, one-company supply model for the sector.

  • Strategic Acquisition: In January 2025, GEON Performance Solutions acquired Foster Corporation, a 36-year-old compounder of biomedical polymers, bioresorbable polymers, and PEEK and TPUs thermoplastic polyurethane elastomers. This was GEON's fourth acquisition in 2020 and is further consolidation of specialty polymer compounders serving the medical device sector.
  • Expansion of Distribution Networks: Foster Medical Compounds appoints Formerra as their North and South American distributor of medical compounds, post acquisition by GEON, in August 2025. This extends Formerra's regional coverage for healthcare polymer distribution. Distribution partnerships enable manufacturing of biomedical polymers to serve OEM customers, without the need for the biomedical polymer manufacturer to build regional sales networks.
  • Neural Regeneration Scaffolds Acquisition: Toray Industries, in October 2025, acquired a neural regeneration scaffold company in Japan, to enhance its fiber, and neural regeneration scaffold solutions with biodegradable polymer technologies and scaffold solutions. The acquisitions of specialized regenerative medicine capabilities demonstrate the increased competition for neural scaffold technology.
  • Domestic Feedstock Manufacturing Investment: The first unit of Balrampur Chini Mills' Bioyug polylactic acid (PLA) manufacturing plant in Lakhimpur Kheri, India, was completed in February 2025, as part of its ₹2,880 crore integrated sugarcane to PLA value-chain project. This project aims to produce 80,000 tons per year of capacity. This project will reduce India's reliance on imported PLA feedstock, which is a key ingredient in biodegradable sutures and implants.
  • Opening of A Medical Applications Center: Evonik opened its largest medical device applications center in Shanghai and offers research, development and processing of bioresorbable medical device components For the Asian market. These regional applications centers will cut the development time of medical device components for customers who previously had to send their projects to be done in either Europe or the USA.

This investment positioning indicates that biodegradable medical polymer suppliers will adopt a multi-pronged strategy of acquisition, distribution, and regional manufacturing investment. This will impact the implant and drug-delivery markets in the coming years.

Strategic Growth Opportunities in the Biodegradable Medical Polymer Market

New markets for biodegradable polymers projected for 2024 to 2026 extend beyond traditional surgical markets. Lucintel's latest report identifies these markets as cardiovascular, neural, and combination device markets. Manufacturers of biodegradable polymers will move up market to more sophisticated, complex, and higher priced products as these markets grow.

  • Bioresorbable Cardiovascular Scaffolds: Determination of the safety profiles for vascular scaffolds made of polylactide compared to permanent metal stents in the long-term ABSORB IV trial brought interest back to biodegradable cardiovascular scaffolds and devices. The newer generations of scaffolds address the issue of target lesion failure. This is a complex, high-value area of the market that few polymer manufacturers can adequately serve.
  • Neural Tissue Regeneration Scaffolds: There has been great investment and interest to commercially develop neural tissue engineering scaffolds evidenced by large, established materials companies buying specialized biomedical scaffold companies. New opportunities for scaffold technology in neurology, a currently untapped market, have high value.
  • Combination Drug-Device Products: There is a significant focus on pharmaceutical polymers designed for sustained and controlled drug release integrated with structural implants. Drug delivery systems account for nearly 30% of anticipated applications in 2026. There will be a premium placed on combination products as sustained and controlled drug delivery systems are favored by the pharmaceutical industry.
  • Geographic Expansion Into Domestic Feedstock Production: Countries solely dependent on imported polylactic acid are starting to produce locally, the fastest growing segment of this market being bioresorbable polymers in India at an estimated CAGR of 19.1% through 2036. With a focus on the domestic production of medical-grade polymers, countries will grant preferential access to early manufacturing partners.
  • Aftermarket Compounding and Custom Formulation Services: Specialty compounders that offer custom medical polymer formulations and provide cleanroom processing and regulatory support are becoming the preferred partners for companies without the capability of materials science. This separation from the raw polymer sale creates a service layer that enables suppliers to retain a steady income from a particular development of a device rather than a one-time sale.

Across these five paths, higher growth is found in technically advanced applications which use biodegradable polymers to combine with drugs, neural tissue or cardiovascular tissue rather than just basic absorbable sutures. Suppliers with the capability of producing cardiovascular and neural scaffolds will be able to meet customer demands not fulfilled by bulk polymer producers.

Biodegradable Medical Polymer Market Drivers and Challenges

Although safety concerns about devices and rising material costs may discourage broader use of biodegradable materials, higher adoption of more absorbable implants and the growing interest in controlled-release drug delivery systems are expected to help drive biodegradable polymers' growth between now and 2026, according to a recent Lucintel report.

Drivers

  • Absorbable Implants: The use of absorbable implants is predicted to increase greatly in the coming years. Because surgeons are now favoring implants that avoid the need for follow-up surgery to remove the implants, demand for implants will grow in a variety of specialties of surgery. Polylactic acid is estimated to comprise 35% of the global market by 2026.
  • Drug Delivery Systems: 2026 is expected to see a 30% market share for controlled release drug delivery systems as a result of the pharmaceutical industry's focus on local release rather than systemic release. This focus will drive polymer-based combined drug delivery systems.
  • Improved Manufacturing Process: The shift to injection molding has driven a 40% increase in the use of biodegradable polymers, mainly due to cost efficiency. continued improvement in manufacturing will result in a larger market service for biodegradable polymers.
  • Investments in Regional Supply Chain: The manufacturing of polylactic acid is increasing in countries previously dependent upon import. India's bioresorbable polymer segment is expected to have the fastest growth at 19.1% CAGR by 2036. Regional supply chain investments will allow manufacturing of biodegradable polymers to be more widely distributed to lower concentrated regions.
  • Fiber-Based Wound Care Applications: Fibers are estimated to encompass a major 38% share of biodegradable polymer forms by 2026. The increasing demand for surgical sutures and wound care drives fiber-based absorbable products. With the increasing volume of minimally invasive surgeries, fiber-based absorbable products will continue to anchor the steady and high volume baseline demand.

Challenges

  • High Cost Materials: Biodegradable polymers like PLA cost approximately twice as much as traditional materials in some markets resulting in limited adoption by cost-conscious device manufacturers and healthcare systems.
  • Device Safety and Target Lesion Failure Risk: There are slightly higher target lesion failure rates shown in long-term studies of bioresorbable vascular scaffolds compared to metallic stents, and consequently, patient selection is of critical importance to minimize complications.
    • Certification and Compliance Complexity: ISO 13485 certification and cleanroom manufacturing add barriers for smaller compounders to enter the medical-grade biodegradable polymer production.

Striking the right balance in these areas will distinguish winners from losers. Suppliers offering cost effective compliance and safety with regional supply diversification will win the decade long race against competitors still charging premium prices and unresolved performance concerns.

List of Biodegradable Medical Polymer Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies biodegradable medical polymer market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biodegradable medical polymer market companies profiled in this report include-

  • Evonik Industries AG
  • Corbion N.V.
  • Mitsui Chemicals Inc.
  • Poly Medicure Limited
  • KLS Martin SE & Co. KG
  • BASF SE
  • NatureWorks LLC
  • Arkema SA
  • Eastman Chemical Company
  • Foster LLC

Biodegradable Medical Polymer Market by Segment

The study includes a forecast for the global biodegradable medical polymer market by material type, product form, application, and region.

Biodegradable Medical Polymer Market by Material Type [Value ($B) from 2019 to 2035]:

  • Ceramic Matrix Composites
  • Oxide Ceramics
  • Non-Oxide Ceramics
  • Advanced Porous Ceramics

Biodegradable Medical Polymer Market by Product Form [Value ($B) from 2019 to 2035]:

  • Powder
  • Tiles
  • Coatings
  • Fibers
  • Bulk

Biodegradable Medical Polymer Market by Application [Value ($B) from 2019 to 2035]:

  • Drug Delivery
  • Implants
  • Sutures
  • Others

Biodegradable Medical Polymer Market by Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Biodegradable Medical Polymer Market

Improvement of bioresorbable implants and drug-delivery polymer technology will continue through 2026 as manufacturers produce more while new regulations in major markets are confirmed. According to Lucintel, new capacities for building absorbable medical materials supply chains will grow significantly in the coming years.

  • The United States: Data from Abbott's ABSORB IV trial publication in 2023 and references in 2025 literature, support long term safety of polylactide-based bioresorbable vascular scaffolds compared to metal stents. Most US device manufacturers are at the forefront of next generation resorbable cardiovascular technology due to continuous research on 3D Printing of PLLA-based scaffolds
  • China: Evonik's bioresorbable medical devices semifinished components opened its processing center in Shanghai. This allows China to strengthen its manufacturing and innovation services across Asia for biodegradable polymers.
  • Germany: Evonik continued building its RESOMER bioresorbable polymer platform citing longer safety studies of its poly-lactide-glycolide copolymer polymer that supports greater safety and efficacy in use cases where sutures, orthopedics, and drug delivery are combined. Continued investments across its Darmstadt and Birmingham, Alabama facilities strengthen Germany's position as a primary source of GMP-grade bioresorbable medical polymers.
  • India: Balrampur Chini Mills established the first unit of its Bioyug polylactic acid biopolymer plant in Lakhimpur Kheri, Uttar Pradesh, in February 2025, as part of its ₹2,880 crore sugarcane to PLA integrated project targeting 80,000 tonnes of annual capacity. This plant is the first major PLA production facility in India, addressing the country's need for biodegradable medical-grade polymer feedstock.
  • Japan: Toray Industries' acquisition of a Japanese biomedical scaffolds startup in October 2025 further augments its fibers and scaffolds for neural tissue regeneration built on biodegradable polymer technology. This acquisition adds Japanese materials companies to the next generation of resorbable scaffold technology for regenerative medicine.

Features of the Global Biodegradable Medical Polymer Market

  • Market Size Estimates: biodegradable medical polymer market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: biodegradable medical polymer market size by material type, product form, application, and region in terms of value ($B).
  • Regional Analysis: biodegradable medical polymer market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different material types, product forms, applications, and regions for the biodegradable medical polymer market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biodegradable medical polymer market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the biodegradable medical polymer market by material type (ceramic matrix composites, oxide ceramics, non-oxide ceramics, and advanced porous ceramics), product form (powder, tiles, coatings, fibers, and bulk), application (drug delivery, implants, sutures, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 6 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Biodegradable Medical Polymer Market by Material Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Material Type
  • 4.3 Ceramic Matrix Composites : Trends and Forecast (2019 to 2035)
  • 4.4 Oxide Ceramics : Trends and Forecast (2019 to 2035)
  • 4.5 Non-Oxide Ceramics : Trends and Forecast (2019 to 2035)
  • 4.6 Advanced Porous Ceramics : Trends and Forecast (2019 to 2035)

5. Global Biodegradable Medical Polymer Market by Product Form

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Product Form
  • 5.3 Powder : Trends and Forecast (2019 to 2035)
  • 5.4 Tiles : Trends and Forecast (2019 to 2035)
  • 5.5 Coatings : Trends and Forecast (2019 to 2035)
  • 5.6 Fibers : Trends and Forecast (2019 to 2035)
  • 5.7 Bulk : Trends and Forecast (2019 to 2035)

6. Global Biodegradable Medical Polymer Market by Application

  • 6.1 Overview
  • 6.2 Attractiveness Analysis by Application
  • 6.3 Drug Delivery : Trends and Forecast (2019 to 2035)
  • 6.4 Implants : Trends and Forecast (2019 to 2035)
  • 6.5 Sutures : Trends and Forecast (2019 to 2035)
  • 6.6 Others : Trends and Forecast (2019 to 2035)

7. Regional Analysis

  • 7.1 Overview
  • 7.2 Global Biodegradable Medical Polymer Market by Region

8. North American Biodegradable Medical Polymer Market

  • 8.1 Overview
  • 8.2 North American Biodegradable Medical Polymer Market by Material Type
  • 8.3 North American Biodegradable Medical Polymer Market by Application
  • 8.4 The United States Biodegradable Medical Polymer Market
  • 8.5 Canadian Biodegradable Medical Polymer Market
  • 8.6 Mexican Biodegradable Medical Polymer Market

9. European Biodegradable Medical Polymer Market

  • 9.1 Overview
  • 9.2 European Biodegradable Medical Polymer Market by Material Type
  • 9.3 European Biodegradable Medical Polymer Market by Application
  • 9.4 German Biodegradable Medical Polymer Market
  • 9.5 French Biodegradable Medical Polymer Market
  • 9.6 Italian Biodegradable Medical Polymer Market
  • 9.7 Spanish Biodegradable Medical Polymer Market
  • 9.8 The United Kingdom Biodegradable Medical Polymer Market

10. APAC Biodegradable Medical Polymer Market

  • 10.1 Overview
  • 10.2 APAC Biodegradable Medical Polymer Market by Material Type
  • 10.3 APAC Biodegradable Medical Polymer Market by Application
  • 10.4 Chinese Biodegradable Medical Polymer Market
  • 10.5 Indian Biodegradable Medical Polymer Market
  • 10.6 Japanese Biodegradable Medical Polymer Market
  • 10.7 South Korean Biodegradable Medical Polymer Market
  • 10.8 Indonesian Biodegradable Medical Polymer Market

11. ROW Biodegradable Medical Polymer Market

  • 11.1 Overview
  • 11.2 ROW Biodegradable Medical Polymer Market by Material Type
  • 11.3 ROW Biodegradable Medical Polymer Market by Application
  • 11.4 Middle Eastern Biodegradable Medical Polymer Market
  • 11.5 South American Biodegradable Medical Polymer Market
  • 11.6 African Biodegradable Medical Polymer Market

12. Competitor Analysis

  • 12.1 Product Portfolio Analysis
  • 12.2 Operational Integration
  • 12.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

  • 13.1 Value Chain Analysis
  • 13.2 Growth Opportunity Analysis
    • 13.2.1 Growth Opportunity by Material Type
    • 13.2.2 Growth Opportunity by Product Form
    • 13.2.3 Growth Opportunity by Application
    • 13.2.4 Growth Opportunity by Region
  • 13.3 Emerging Trends in the Global Biodegradable Medical Polymer Market
  • 13.4 Strategic Analysis
    • 13.4.1 New Product Development
    • 13.4.2 Certification and Licensing
    • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

  • 14.1 Competitive Analysis Overview
  • 14.2 Evonik Industries AG
    • Company Overview
    • Biodegradable Medical Polymer Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.3 Corbion N.V.
    • Company Overview
    • Biodegradable Medical Polymer Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.4 Mitsui Chemicals Inc.
    • Company Overview
    • Biodegradable Medical Polymer Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.5 Poly Medicure Limited
    • Company Overview
    • Biodegradable Medical Polymer Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.6 KLS Martin SE & Co. KG
    • Company Overview
    • Biodegradable Medical Polymer Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.7 BASF SE
    • Company Overview
    • Biodegradable Medical Polymer Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.8 NatureWorks LLC
    • Company Overview
    • Biodegradable Medical Polymer Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.9 Arkema SA
    • Company Overview
    • Biodegradable Medical Polymer Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.10 Eastman Chemical Company
    • Company Overview
    • Biodegradable Medical Polymer Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.11 Foster LLC
    • Company Overview
    • Biodegradable Medical Polymer Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

15. Appendix

  • 15.1 List of Figures
  • 15.2 List of Tables
  • 15.3 Research Methodology
  • 15.4 Disclaimer
  • 15.5 Copyright
  • 15.6 Abbreviations and Technical Units
  • 15.7 About Us
  • 15.8 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기